Loading organizations...
Panome Bio operates as a contract research organization, providing next-generation metabolomics and proteomics discovery services. It uses liquid chromatography-mass spectrometry and proprietary bioinformatics tools, offering deep insights into metabolic pathways. This integrated approach enables understanding biomolecules, supporting life sciences research and development.
The company was founded with BioGenerator’s backing, stemming from the Next-Generation Metabolomics™ technology developed by Chief Scientific Officer Dr. Gary Patti. Dr. Patti, a leading metabolomics academic, created advanced analytical software foundational to Panome Bio. Co-founders Edward Weinstein, CEO, and David Smoller identified the need for improved access and data interpretation in complex metabolic experimentation, initiating the company.
Panome Bio serves pharmaceutical and biotech companies, assisting their biomarker discovery and drug development. It offers a complete workflow, from experimental design to data processing, profiling the metabolome and proteome. Its vision is to expand accessibility to these powerful omics capabilities, accelerating breakthroughs in precision medicine and therapeutic innovation.
Panome Bio has raised $6.0M across 1 funding round.
Panome Bio has raised $6.0M in total across 1 funding round.
Panome Bio is a St. Louis-based life sciences company specializing in multi-omics services, including next-generation metabolomics, proteomics, lipidomics, and integrated analysis for biomarker discovery and drug development.[1][2][3] It serves pharmaceutical, biotech, and research organizations by providing untargeted mass spectrometry-based workflows that profile metabolites, proteins, and other biomolecules to uncover metabolic fingerprints, disease mechanisms, and drug responses, addressing limitations in traditional targeted approaches.[2][4] Launched with a $6M Series A in 2022, the company demonstrates strong growth through expansions like phosphoproteomics and transcriptomics services, enabling deeper insights into cancer, aging, and bioreactor optimization.[1][3][5]
Panome Bio emerged from technology developed by Chief Scientific Officer Dr. Gary Patti, whose Next-Generation Metabolomics platform was incubated by BioGenerator, a St. Louis venture builder.[1] Founded in 2022 and headquartered in Saint Louis, Missouri, the company launched with $6M in Series A financing led by BioGenerator Ventures to scale operations, expand labs, and grow its team.[1][3] CEO Edward Weinstein has highlighted the platform's ability to deliver a global metabolite view, driving early traction with biopharma clients seeking advanced biomarker discovery.[1] Pivotal moments include rapid service expansions, such as adding transcriptomics in 2025 and global phosphoproteomics for analyzing protein phosphorylation in disease pathways.[3][5]
Panome Bio stands out in the multi-omics space through proprietary technologies and workflows that outperform legacy methods:
Panome Bio rides the multi-omics revolution in precision medicine and biotech R&D, where integrating metabolomics, proteomics, and beyond reveals phenotype closest to disease—critical as targeted assays fall short on dynamic range and novelty.[1][2][4] Timing aligns with surging demand for untargeted data in oncology, aging, drug metabolism, and cultivated meat bioprocessing, fueled by mass spec advances like Orbitrap Astral and AI bioinformatics.[5][6] Market forces favoring Panome include biopharma's push for biomarkers amid clinical trial failures (e.g., signaling pathway insights for resistance) and the $10B+ omics services sector's shift to integrated platforms.[3][5] It influences the ecosystem by democratizing high-depth analysis for startups and pharma, accelerating discoveries from lab to trials.[1][6]
Panome Bio is poised for accelerated growth by layering services like phosphoproteomics and transcriptomics atop its core metabolomics-proteomics engine, targeting expanding applications in cultivated biotech and clinical translation.[3][5][6] Trends like AI-driven omics integration and single-sample multi-profiling will amplify its edge, potentially capturing share from fragmented providers amid rising bioreactor and personalized medicine needs. Its influence may evolve into a go-to platform for phenotype-driven drug discovery, scaling via partnerships and further funding to redefine biopharma workflows—building directly on its launch promise of unparalleled biomolecule access.[1][2]
Panome Bio has raised $6.0M in total across 1 funding round.
Panome Bio's investors include Telegraph Hill Partners.
Panome Bio has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2023 | $6M Series A | — | Telegraph Hill Partners | Announced |
